Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Anavex Life Sciences Corp.
Anavex Life Sciences Corp. News
Anavex Life Sciences Corp. Quantitative Score
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp. Earnings & Revenue
Anavex Life Sciences Corp. Financials
Table Compare
Compare AVXL metrics with: | |||
|---|---|---|---|
Earnings & Growth | AVXL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | AVXL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | AVXL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | AVXL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Anavex Life Sciences Corp. Income
Anavex Life Sciences Corp. Balance Sheet
Anavex Life Sciences Corp. Cash Flow
Anavex Life Sciences Corp. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Anavex Life Sciences Corp. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Anavex Life Sciences Corp. Executives
| Name | Role |
|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary & Director |
| Ms. Sandra Boenisch CPA, CGA | Principal Financial Officer & Treasurer |
| Dr. Walter E. Kaufmann M.D. | Chief Scientific Officer |
| Dr. Kun Jin Ph.D. | Head of Biostatistics |
| Dr. Terrie Kellmeyer Ph.D. | Senior Vice President of Clinical Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary & Director | 1966 | 828.25K | |
| Ms. Sandra Boenisch CPA, CGA | Principal Financial Officer & Treasurer | Female | 1981 | 194.36K |
| Dr. Walter E. Kaufmann M.D. | Chief Scientific Officer | -- | ||
| Dr. Kun Jin Ph.D. | Head of Biostatistics | -- | ||
| Dr. Terrie Kellmeyer Ph.D. | Senior Vice President of Clinical Development | -- |
Anavex Life Sciences Corp. Insider Trades
| Date | 15 Jan |
| Name | MISSLING CHRISTOPHER U |
| Role | President and CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 166666 |
| Date | 15 Jan |
| Name | MISSLING CHRISTOPHER U |
| Role | President and CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 125000 |
| Date | 15 Jan |
| Name | Boenisch Sandra |
| Role | PFO & Treasurer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 12500 |
| Date | 19 Dec |
| Name | Boenisch Sandra |
| Role | PFO & Treasurer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 12500 |
| Date | 19 Dec |
| Name | MISSLING CHRISTOPHER U |
| Role | President and CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 125000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Jan | MISSLING CHRISTOPHER U | President and CEO | Acquired | A-Award | 166666 |
| 15 Jan | MISSLING CHRISTOPHER U | President and CEO | Acquired | A-Award | 125000 |
| 15 Jan | Boenisch Sandra | PFO & Treasurer | Acquired | A-Award | 12500 |
| 19 Dec | Boenisch Sandra | PFO & Treasurer | Acquired | A-Award | 12500 |
| 19 Dec | MISSLING CHRISTOPHER U | President and CEO | Acquired | A-Award | 125000 |